Statin Myopathy (AHA/ACC/NHLBI)

Slides:

Advertisements

Similar presentations

HPS2-THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events Jane Armitage on behalf of the THRIVE Collaborative Group Financial Disclosure:

Advertisements

Weng TC, et al. J Clin Pharm Ther 2010;35:

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Statin Induce Myotoxicity

Amarenco P, Labreuche J. Lancet Neurol 2009;8:

Characteristics of Large Prospective Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. Alsheikh-Ali, et al. JACC 2007;50:

Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.

Statins induced myopathy

Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

Updates and Perspectives in Diabetic Dyslipidemia

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

Optimizing Statin Therapy

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

Diabetes and Dyslipidemia

Tailoring Statin Therapy in Women

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Metastatic Renal Cell Carcinoma

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Statin Selection in Special Patient Populations: A Case Challenge

Understanding Statin Metabolism

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

TNT Study: Baseline Characteristics of the Patients

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Evaluating LDL-C Recommendations

What's New in Dyslipidemia?

62-year-old Man With Unstable Angina

Statins and Glucose Metabolism: Are All Agents Alike?

Efficacy and Safety of Edoxaban in Patients With AF and HF

PCSK9 Inhibitors and Cardiovascular Outcomes

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

A Patient Journey Through Statin Intolerance

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

A PCP's Guide to Dyslipidemia

Radical New Concepts in Lipid Management

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

Clinicians' Corner in Dyslipidemia

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Monoclonal Antibodies in CVD: What Does the Future Hold?

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

Statins, Obesity, and Hyperlipidemia

LDL Cholesterol.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

How to Optimize Cholesterol Management in High-Risk CV Patients

Incorporating Prostacyclins Into Practice

Latest Lipid Guidelines in Perspective

Approximate Dose Equivalency of Statin LDL-C Efficacy.

New Lipid-Lowering Therapies

Statins and Glucose Metabolism: An Endocrinology Perspective

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

PCSK9 Inhibitors and Statin Intolerance

Achieving Lipid Targets With PCSK9 Inhibition

PCSK9 Inhibitors and Real-World Evidence

Late-Breaking Data on LDL-C Reduction

Presentation transcript:

How Can We Improve Cardiovascular Risk Reduction in Statin-Intolerant Patients?

Statin Myopathy (AHA/ACC/NHLBI)

Incidence of Muscle Adverse Effects

Differences Among Statins?

Reports of Myotoxicity in Major Randomized Trials Using Maximum-dose Statins

PRIMO: Patient Cohort

PRIMO: Risk of Muscular Symptoms With Individual Statins

Timing of Myalgia in PRIMO

Mechanisms of Statin-Induced Myopathy and Rhabdomyolysis

Factors That Increase the Risk of Statin-Induced Myopathy

Coenzyme Q10 Supplementation for the Treatment of Statin Associated Myopathy

GAUSS: Phase 2 AMG 145 in Statin-Intolerant Patients

GAUSS: Baseline Characteristics

GAUSS: Effect of AMG 145 on Percentage Change in LDL-C From Baseline

GAUSS: Percentage of Patients Achieving LDL-C Goals

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)